DUBLIN--(BUSINESS WIRE)--The "Liver Transplant Rejection - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Liver Transplant Rejection - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Liver Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Transplant Rejection (Immunology) pipeline guide also reviews key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 5 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 2, 1 and 1 molecules, respectively.
Liver Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies Featured
- Alexion Pharmaceuticals Inc.
- Dompe Farmaceutici SpA
- Novartis AG
- RedHill Biopharma Ltd.
- Veloxis Pharmaceuticals A/S
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mjbl9x/liver_transplant?w=4
